厄罗替尼治疗晚期非小细胞肺癌16例临床分析

The preliminary clinical analysis of Erlotinib in 16 patients with advanced non-small cell lung cancer

目的:观察厄罗替尼治疗晚期非小细胞肺癌(NSCLC)患者的疗效和不良反应。方法:16例非小细胞肺癌患者口服厄罗替尼,150mg/次,1次/d,直至病情进展或出现不能耐受的不良反应。结果:16例患者客观有效率为31%(5/16),疾病控制率为50%(8/16),中位无疾病进展时间为2.5个月(0.5～8.0个月),中位生存时间为5.6个月(0.5～13.0个月)。不良反应主要为皮疹。结论:厄罗替尼对既往化疗失败的转移性非小细胞肺癌患者有较好的疗效和安全性。

Objective： To evaluate the efficacy of erlotinib on advanced NSCLC, and observe its adverse events. Methods： Sixteen pathologically confirmed advanced NSCLC patients had received chemotherapy at least one regimen. Erlotinib （150 mg） was orally administered daily till disease progression or intolerable adverse events developed. Results： In the 16 patients, the objective response rate was 31%, and the disease control rate was 50% ; the median progression free survival time was 2.5 months （0.5--8.0 months）, and the median survival time was 5.6 months （0.5--13.0 months）. Adverse events were generally mild （grade Ⅰ or Ⅱ ）, including skin rash （75%） No grade Ⅳ drug-related adverse event occurred. Conclusion： Erlo tinib is effective and safe for metastatic NSCLC patients who have failed to previous chemotherapy.